ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
about
Pharmacology of iron transportComplex Formation of ICL670 and Related Ligands with FeIIIand FeIIOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.Deferasirox--an oral agent for chronic iron overload.Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbilAdvances in iron chelation: an update.Design of iron chelators with therapeutic application.Current and future therapy in haemochromatosis and Wilson's disease.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.Deferasirox: an update.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups.Role of pharmacogenetics on deferasirox AUC and efficacy.Inhibitory effects of deferasirox on the structure and function of bovine liver catalase: a spectroscopic and theoretical study.Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.Deferasirox in Indian children with thalassemia major: 3 years experience.Ability of deferasirox to bind iron during measurement of iron.The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.Attenuation of acute and chronic liver injury in rats by iron-deficient diet.Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model.Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.
P2860
Q27009387-7C82D503-111B-4671-8852-C806E79DE8E1Q29308239-6B0CFD0C-4639-478F-A8BB-6C110A078E37Q31037298-3DC42BC0-01AC-4D92-BD6C-B90EDC9AD7A7Q33245186-CE4423BD-3A65-412A-B992-5D220F368061Q33909024-97D48DD9-7464-4BB8-A778-3AB3F2FA6FA7Q33944180-8CA270C1-911E-4921-9141-EAD4C726F6CBQ33958533-99D3ACBB-643D-4B54-ADBA-22AF96ED33E6Q34174307-5EEEAA48-A44B-4935-A0E7-A6EB9E5FFDB1Q34258805-62123D78-1A3A-47C7-8D02-DEFD8D924365Q35593984-53EF1684-2583-456B-97B3-DA389186A249Q35919222-96D92313-43DA-4163-8D40-4AE8465AEA31Q36518462-538832A8-4460-4F34-AB38-59D0D48330D8Q36851507-C83A76B2-3366-4C43-84D8-BEC0B91C6461Q37650465-215F4C24-E96D-43DD-A1B7-DAEFD037BDECQ38099045-ACBF5AF2-ABA5-4366-B19B-6022370E01A4Q39672604-372705F5-6A94-47D9-856A-64D955480327Q39865051-EEFA8EDD-76E5-4AE8-BD89-BE7D7ACE416FQ41585207-771149CD-6E28-4D98-9751-90D28D284162Q41687355-EEB8427E-C319-46F4-9698-4CB854F471AEQ42183461-623ED494-5756-4D74-B631-B59BF11C60B0Q43085663-BC25C4CB-89B4-4B9E-8C84-00C0022F229DQ43156449-0770356F-117C-4ECF-BE7D-00CB29447650Q43268656-68AF8779-FF69-47A6-8D0A-BD34B0C66EA8Q43413539-C5F5D35F-FAAF-4BFD-9F96-9C1E22D34E55Q46254751-E4FEDC08-84C9-4339-8A37-01D2952304B6Q46886612-98C56D33-A4AF-436E-BE51-8B2E40209113Q50482668-806C5287-271A-4442-ADED-F58952EB6FBAQ51320316-475430A5-A0C1-4642-97F2-34C93BBB4C3EQ52147741-A2269838-C86C-4C81-A710-364427F3858E
P2860
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@ast
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@en
type
label
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@ast
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@en
prefLabel
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@ast
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@en
P2093
P356
P1433
P1476
ICL670A: a new synthetic oral ...... ed rat heart cells in culture.
@en
P2093
P304
P356
10.1182/BLOOD.V97.4.1115
P407
P577
2001-02-01T00:00:00Z